FirstWord

Summit abandoned plans to raise $500 million, while Novo Nordisk said some pieces of patient data were accessed in a security incident.

A Phase III trial of the antibody oligonucleotide conjugate is already enrolling patients with facioscapulohumeral muscular dystrophy.

The biotech proposed to sell 23.3 million shares between $14 and $16; if it prices at the high end, Kardigan could earn a valuation of about $1.4 billion.

The company has also aligned with the FDA on a recommended dose for the upcoming chronic myeloid leukaemia (CML) trial, expected to start in the second half.

Head-to-head psoriasis study shows superior skin-clearance rates across all primary and key secondary endpoints.

— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc a...

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoc...

Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety concerns2 W...

TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced p...

NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 20...